Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.37 |
| ▸ | RAF1 | P04049 | 10/20 | 0.36 |
| ▸ | CSF1R | P07333 | 7/20 | 0.35 |
| ▸ | FLT3 | P36888 | 7/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.34 |
| ▸ | KIT | P10721 | 3/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.34 |
| ▸ | BRAF | P15056 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217282 | 0.87 | RAF1 (0.39) | MAPK14RAF1 | |
| SCHEMBL3217531 | 0.84 | MAPK14 (0.40) | MAPK14 | |
| SCHEMBL3220838 | 0.84 | RAF1 (0.33) | MAPK14RAF1BRAF | |
| SCHEMBL3212515 | 0.82 | RAF1 (0.36) | MAPK14RAF1CSF1RFLT3BRAF | |
| SCHEMBL197313 | 0.78 | FLT3 (0.38) | MAPK14RAF1CSF1RFLT3BRAF | |
| SCHEMBL195958 | 0.77 | RPS6KB1 (0.46) | MAPK14 | |
| SCHEMBL3218770 | 0.76 | RAF1 (0.42) | MAPK14RAF1 | |
| SCHEMBL13487790 | 0.76 | RAF1 (0.41) | MAPK14RAF1 | |
| SCHEMBL3204272 | 0.74 | MAPK14 (0.41) | MAPK14 | |
| SCHEMBL3204040 | 0.73 | FLT3 (0.38) | MAPK14RAF1FLT3KITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010019930-A1 | UREA DERIVATIVES AS INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | MAPK14 33/4885RAF1 74/4885CSF1R 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.